Publication List 1998

1984-94, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022

24 （166）	Miyazono K, ten Dijke P, Souchelnytskyi S, Nakao A, Imamura T, Hanai J, Kawabata M, and Heldin CH. Serono Symposia on "Inhibin, activin, follistatin...Recent advances and future views". pp. 277-284.
23 （165）	Miyazono K Smad proteins: signal transducers for BMP and TGF-β/activin J Bone Miner Metab. 1999;16(3):133-8.
22 （164）	Nakamura K, Yasaka N, Asahina A, Kato M, Miyazono K, Furue M, Tamaki K. Increased numbers of CD68 antigen positive dendritic epidermal cells and upregulation of CLA (cutaneous lymphocyte-associated antigen) expression on these cells in various skin diseases. J Dermatol Sci. 1998 Dec;18(3):170-80.
21 （163）	Saitoh M, ten Dijke P, Miyazono K, Ichijo H. Cloning and characterization of p70^S6Kβ defines a novel family of p70 S6 kinases. Biochem Biophys Res Commun. 1998 Dec 18;253(2):470-6.
20 （162）	Li J, Tsuji K, Komori T, Miyazono K, Wrana JL, Ito Y, Nifuji A, Noda M. Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROS17/2.8 cells and primary rat calvaria cells. J Biol Chem. 1998 Nov 20;273(47):31009-15.
19 （161）	Yamagishi T, Nakajima Y, Sampath TK, Miyazono K, Nakamura H. Bone morphogenetic protein 2 acts synergistically with transforming growth factor β3 in endothelial-mesenchymal cell transformation during chick heart development. Ann N Y Acad Sci. 1998 Oct 23;857:276-8.
18 （160）	Nishihara A, Hanai JI, Okamoto N, Yanagisawa J, Kato S, Miyazono K, Kawabata M. Role of p300, a transcriptional coactivator, in signalling of TGF-β. Genes Cells. 1998 Sep;3(9):613-23.
17 （159）	Nishitoh H, Saitoh M, Mochida Y, Takeda K, Nakano H, Rothe M, Miyazono K, Ichijo H. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell. 1998 Sep;2(3):389-95.
16 （158）	Shimizu T, Mehdi R, Yoshimura Y, Yoshikawa H, Nomura S, Miyazono K, Takaoka K. Sequential expression of bone morphogenetic protein, tumor necrosis factor, and their receptors in bone-forming reaction after mouse femoral marrow ablation. Bone. 1998 Aug;23(2):127-33.
15 （157）	Inoue H, Imamura T, Ishidou Y, Takase M, Udagawa Y, Oka Y, Tsuneizumi K, Tabata T, Miyazono K, Kawabata M. Interplay of signal mediators of decapentaplegic (Dpp): molecular characterization of mothers against dpp, Medea, and daughters against dpp. Mol Biol Cell. 1998 Aug;9(8):2145-56.
14 （156）	Goto D, Yagi K, Inoue H, Iwamoto I, Kawabata M, Miyazono K, Kato M. A single missense mutant of Smad3 inhibits activation of both Smad2 and Smad3, and has a dominant negative effect on TGF-β signals. FEBS Lett. 1998 Jul 3;430(3):201-4.
13 （155）	Takeda K, Ichijo H, Fujii M, Mochida Y, Saitoh M, Nishitoh H, Sampath TK, Miyazono K. Identification of a novel bone morphogenetic protein-responsive gene that may function as a noncoding RNA. J Biol Chem. 1998 Jul 3;273(27):17079-85.
12 （154）	Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J. 1998 Jul 15;17(14):4056-65.
11 （153）	Horie K, Yamashita H, Mogi A, Takenoshita S, Miyazono K. Lack of transforming growth factor-β type II receptor expression in human retinoblastoma cells. J Cell Physiol. 1998 Jun;175(3):305-13.
10 （152）	Hori Y, Katoh T, Hirakata M, Joki N, Kaname S, Fukagawa M, Okuda T, Ohashi H, Fujita T, Miyazono K, Kurokawa K. Anti-latent TGF-β binding protein-1 antibody or synthetic oligopeptides inhibit extracellular matrix expression induced by stretch in cultured rat mesangial cells. Kidney Int. 1998 Jun;53(6):1616-25.
9 （151）	Wada Y, Kataoka H, Yokose S, Ishizuya T, Miyazono K, Gao YH, Shibasaki Y, Yamaguchi A. Changes in osteoblast phenotype during differentiation of enzymatically isolated rat calvaria cells. Bone. 1998 May;22(5):479-85.
8 （150）	Lu SL, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K, Yuasa Y. HNPCC associated with germline mutation in the TGF-β type II receptor gene. Nat Genet. 1998 May;19(1):17-8.
7 （149）	Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998 May 1;17(9):2596-606.
6 （148）	Oeda E, Oka Y, Miyazono K, Kawabata M. Interaction of Drosophila inhibitors of apoptosis with thick veins, a type I serine/threonine kinase receptor for decapentaplegic. J Biol Chem. 1998 Apr 17;273(16):9353-6.
5 （147）	Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 1998 Mar;9(1):49-61.
4 （146）	Roijer E, Miyazono K, Astrom AK, Geurts van Kessel A, ten Dijke P, Stenman G. Chromosomal localization of three human genes encoding members of the TGF-β superfamily of type I serine/threonine kinase receptors. Mamm Genome. 1998 Mar;9(3):266-8.
3 （145）	Takase M, Imamura T, Sampath TK, Takeda K, Ichijo H, Miyazono K, Kawabata M. Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun. 1998 Mar 6;244(1):26-9.
2 （144）	Shimizu A, Kato M, Nakao A, Imamura T, ten Dijke P, Heldin CH, Kawabata M, Shimada S, Miyazono K. Identification of receptors and Smad proteins involved in activin signalling in a human epidermal keratinocyte cell line. Genes Cells. 1998 Feb;3(2):125-34.
1 （143）	Takenoshita S, Mogi A, Nagashima M, Yang K, Yagi K, Hanyu A, Nagamachi Y, Miyazono K, Hagiwara K. Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-β and activin signal transduction pathway. Genomics. 1998 Feb 15;48(1):1-11.